Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation

NCT07830576 | Recruiting

• 2 other identifiers: 2026KY-2492025AHGXZK10006
• Study Type: observational
• Target: 205
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline indicators for patients with colorectal liver metastases (CRLM) after surgery. By combining micro-level radiomics signatures reflecting tumor micro-heterogeneity with macro-level clinical parameters (such as liver function and tumor biomarkers), the study aims to accurately evaluate individual post-operative prognostic risks. This quantitative tool will provide reliable decision support for clinicians to customize post-operative follow-up and personalized adjuvant treatment strategies.

Conditions

Colorectal Neoplasms; Liver Neoplasms; Colorectal Liver Metastases

Keywords

Colorectal Liver Metastases; Radiomics; Magnetic Resonance Imaging; Nomogram; Prognosis

Outcome Measures

Primary Outcomes (1)

• Recurrence-Free Survival (RFS)

  Recurrence-free survival (RFS) is defined as the time from the date of surgical resection to the date of first tumor recurrence (local, regional, or distant) or death from any cause, whichever occurs first.

  Up to 5 years post-surgery

Study Arms (1)

CRLM Surgical Cohort

A multicenter cohort consisting of patients with colorectal liver metastases who underwent surgical resection. Preoperative magnetic resonance imaging (MRI) is utilized for 3D modeling and three-dimensional reconstruction of the liver and lesions, from which key spatial/morphological features and systemic clinical parameters are analyzed to predict post-operative recurrence-free survival.

Procedure: Multimodal Predictive Evaluation

Interventions

Multimodal Predictive Evaluation PROCEDURE

Observational and non-invasive assessment based on preoperative MRI-derived 3D modeling and three-dimensional lesion reconstruction, combined with clinical parameters, to build a survival prediction model. No experimental intervention is assigned.

CRLM Surgical Cohort

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients diagnosed with colorectal liver metastases who underwent surgical resection across multiple participating clinical centers, featuring high-quality preoperative liver MRI scans and complete clinical follow-up histories.

You may qualify if:

• Age \>= 18 years old. Confirmed diagnosis of colorectal cancer with liver metastases (CRLM). Underwent surgical resection for colorectal liver metastases. Preoperative liver magnetic resonance imaging (MRI) was performed with high-quality images available for 3D radiomics feature extraction.
• Complete baseline clinical, laboratory, and post-operative follow-up survival data.

You may not qualify if:

• Patients who received local ablation only (such as radiofrequency ablation) without surgical resection.
• Preoperative MRI images with severe artifacts or poor quality that prevent high-throughput radiomics analysis.
• Concurrent history of other primary malignant neoplasms. Missing key clinical variables or lost to follow-up immediately after surgical intervention.

Sponsors & Collaborators

• Anhui Provincial Hospital: lead
• Anhui Provincial Cancer Hospital: collaborator

Study Sites (1)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, 230001, China

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms; Liver Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Liver Diseases

Study Officials

• Jizhou Wang, MD, PhD

  The First Affiliated Hospital of University of Science and Technology of China

  PRINCIPAL INVESTIGATOR

Central Study Contacts

can zhang

CONTACT

+8615755077865; 15755077865@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 31, 2026
• First Posted: September 21, 2026
• Study Start: February 1, 2017
• Primary Completion: September 1, 2026
• Study Completion: September 1, 2026
• Last Updated: September 21, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)